Phase i study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

Investigational New Drugs

Volumn 31, Issue 3, 2013, Pages 734-741

  Awada, A H ^a   Dumez, H ^b   Hendlisz, A ^a   Wolter, P ^b   Besse Hammer, T ^a   Uttenreuther Fischer, M ^c   Stopfer, P ^c   Fleischer, F ^c   Piccart, M ^a   Schoffski P ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Afatinib; BIBW 2992; Epidermal growth factor receptor; Pharmacokinetics; Phase I; Tyrosine kinase inhibitor

Indexed keywords

AFATINIB; DOCETAXEL; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; TAXOID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BELGIUM; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; VOMITING; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; MIDDLE AGED; NEOPLASMS; PHASE 1 CLINICAL TRIAL; SKIN DISEASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; SKIN DISEASES; TAXOIDS;

EID: 84879092054     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9880-0     Document Type: Article

References (28)

1. Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21(2):177-184. doi: 10.1016/j.ceb.2008.12.010
2. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4):31-39
3. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23(11):2445-2459. doi: 10.1200/JCO.2005.11.890
4. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702-4711. doi: 10.1038/onc.2008.109
5. Solca F, Dahl C, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. doi: 10.1124/jpet.1112.197756
6. Reid A, Vidal L, Shaw H, de Bono J (2007) Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43(3):481-489. doi: 10.1016/j.ejca.2006.11.007
7. Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries EG (2008) A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98(1):80-85. doi: 10.1038/sj.bjc.6604108
8. Marshall J, Hwang J, Eskens FALM, Burger, Malik S, Uttenreuther-Fischer M, Stopfer P, Ould Kaci M, Cohen RB, Lewis NL (2012) A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Investigational New Drugs. (in press)
9. Agus DB, Terlizzi E, Stopfer P, Amelsberg A, Gordon MS (2006) A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. J Clin Oncol 24(18S):2074
10. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono J, Plummer R (2010) Phase I trial of the irrevisible ErbB1 (EGFR) and ErbB2 (HER2) kinase inhibitor BIBW 2992 in patients with advanced solid tumours. J Clin Oncol 28(25):3965-3972
11. Solca F, Baum A, Himmelsbach F, Amelsberg A, Adolf G (2006) Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 kinase inhibitor in combination with cytotoxic agents. Eur J Cancer Suppl 4(12):172
12. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 22(5):777-784. doi: 10.1200/JCO.2004.08.001
13. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 22(5):785-794
14. von Pawel J, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Reck M (2007) A double blind phase II study of BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). In: American Society of Clinical Oncology Chicago, IL, USA, 1-5 June
15. Davies A, Hesketh P, Beckett L, Lau D, Mack P, Lara P, Jernigan J, LaPointe J, Gandara D (2007) Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): Overcoming hypothesized antagonism. ASCO Meeting Abstracts 25 (18-suppl):7618
16. Davies A, Lara P, Lau D, Mack P, Gumerlock P, Gandara D (2005) Intermittent erlotinib in combination with docetaxel (DOC): Phase I schedules designed to achieve pharmacodynamic separation. ASCO Meeting Abstracts 23 (16-suppl):7038
17. Gumerlock P, Pryde B, Kimura T, Galvin I, Scott S, Mack P, Davies A, Gandara D (2003) Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 22(662a):abstr 2661
18. Mahaffey CM, Davies AM, Lara PN Jr, Pryde B, Holland W, Mack PC, Gumerlock PH, Gandara DR (2007) Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer 8(9):548-553
19. Solca F, Schweifer N, Baum A, Rudolph D, Amelsberg A, Himmelsbach F, Beug H (2005) BIBW 2992, an irreversible dual EGFR/HER2 kinase inhibitor, shows activity on L858R/T790M EGFR mutants. Clin Cancer Res 11(23):A242
20. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA (2012) Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncology 13(5):539-548
21. Marshall J, Shapiro GI, Terlizzi P, Stopfer P, Amelsberg A, Gordon M (2008) A Phase I dose escalation trial of BIBW 2992, an irreversible EGFR/HER2 kinase inhibitor, for 20 and 13 days in combination with docetaxel every 21 days. In: ESMO, Stockholm, Sweden, September 2008, pp viii153-165
22. Campas C, Bolos J (2008) BIBW-2992. Dual EGFR/HER2 inhibitor oncolytic. Drugs Future 33(8):649-654
23. Pronk LC, Stoter G, Verweij J (1995) Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Cancer Treat Rev 21(5):463-478
24. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncology 13(5):528-538
25. Riely G, Rizvi N, Kris M, Milton D, Solit DB, Rosen N, Senturk E, Azzoli C, Brahmer J, Sirotnak FM, Seshan V, Fogle M, Ginsberg MS, Miller V, Rudin CM (2009) Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 27(27):264-270
26. Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, Pfister DG, Rizvi NA (2007) A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 59(4):467-475. doi: 10.1007/s00280-006-0286-6
27. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL (2007) A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res 13(9):2768-2776. doi: 10.1158/1078-0432.CCR-06-2362
28. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36(2):99-114